These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 8427780

  • 21. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR.
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [Abstract] [Full Text] [Related]

  • 22. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
    Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR.
    Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
    [Abstract] [Full Text] [Related]

  • 23. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR.
    Anticancer Res; 1996 Apr; 16(1):33-8. PubMed ID: 8615631
    [Abstract] [Full Text] [Related]

  • 24. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
    Kelland LR, Barnard CF, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KR.
    Cancer Res; 1994 Nov 01; 54(21):5618-22. PubMed ID: 7923207
    [Abstract] [Full Text] [Related]

  • 25. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 26. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.
    Goddard PM, Valenti MR, Harrap KR.
    Ann Oncol; 1991 Sep 01; 2(8):535-40. PubMed ID: 1793720
    [Abstract] [Full Text] [Related]

  • 27. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
    Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB.
    Med Pediatr Oncol; 2002 Dec 01; 39(6):573-80. PubMed ID: 12376980
    [Abstract] [Full Text] [Related]

  • 28. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA.
    Cancer Res; 1992 Oct 15; 52(20):5674-80. PubMed ID: 1327513
    [Abstract] [Full Text] [Related]

  • 29. [Isolation of cisplatin-resistant subline from human ovarian cancer cell line and analysis of its cell-biological characteristics].
    Yoshiya N, Adachi S, Misawa Y, Yuzawa H, Honda T, Kanazawa K, Takeuchi S Tanaka K, Tanaka K.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan 15; 41(1):7-14. PubMed ID: 2647872
    [Abstract] [Full Text] [Related]

  • 30. [Antitumor activity of platinum analogs against human ovarian tumors heterotransplanted into nude mice].
    Sawada M, Ozaki M, Hongo J, Hirota Y, Inagaki M, Taniguchi H, Tateishi R, Mori Y.
    Gan To Kagaku Ryoho; 1987 Mar 15; 14(3 Pt 1):693-8. PubMed ID: 3548596
    [Abstract] [Full Text] [Related]

  • 31. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR.
    Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660
    [Abstract] [Full Text] [Related]

  • 32. [Cross resistance of a new platinum analogue, ACT-078, to CDDP and CBDCA].
    Misawa T, Higashide K, Konda C, Maeda O, Hasegawa N, Kikkawa F, Tomoda Y.
    Gan To Kagaku Ryoho; 1995 Mar 15; 22(4):569-71. PubMed ID: 7887652
    [No Abstract] [Full Text] [Related]

  • 33. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
    Nicolson MC, Orr RM, O'Neill CF, Harrap KR.
    Neoplasma; 1992 Mar 15; 39(3):189-95. PubMed ID: 1528325
    [Abstract] [Full Text] [Related]

  • 34. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
    Ara G, Kusumoto T, Korbut TT, Cullere-Luengo F, Teicher BA.
    Cancer Res; 1994 Mar 15; 54(6):1497-502. PubMed ID: 8137254
    [Abstract] [Full Text] [Related]

  • 35. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
    Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF.
    Cancer Res; 1987 Jan 15; 47(2):414-8. PubMed ID: 3539322
    [Abstract] [Full Text] [Related]

  • 36. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
    Teicher BA, Holden SA, Herman TS, Sotomayor EA, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E.
    Int J Cancer; 1991 Jan 21; 47(2):252-60. PubMed ID: 1846350
    [Abstract] [Full Text] [Related]

  • 37. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ, Abel G, Kelland LR, Harrap KR.
    Br J Cancer; 1994 Jan 21; 69(1):1-7. PubMed ID: 8286188
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
    Orr RM, O'Neill CF, Nicolson MC, Barnard CF, Murrer BA, Giandomenico CM, Vollano JF, Harrap KR.
    Br J Cancer; 1994 Sep 21; 70(3):415-20. PubMed ID: 8080724
    [Abstract] [Full Text] [Related]

  • 39. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
    Jones AC, Wilson PA, Steel GG.
    Cancer Chemother Pharmacol; 1984 Sep 21; 13(2):109-13. PubMed ID: 6380788
    [Abstract] [Full Text] [Related]

  • 40. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR.
    Cancer Res; 1992 Apr 01; 52(7):1710-6. PubMed ID: 1312897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.